Bernard Chauvin
Independent Director @ EyeTechCare
Bernard Chauvin is a Series A investor at EyeTechCare focused on Medical and Health Care. Bernard Chauvin, a renowned authority in the field of ophthalmology, sits on the company's Board of Directors.March 12, 2013 – EyeTechCare SA, has secured a third round of funding amounting to EUR 10 million. Bernard Chauvin, a private investor, has taken an equity stake in the company alongside two of the existing investors which alsocontributed to this round of funding: the capital investment company Omnes Capital (formerly Crédit Agricole Private Equity) and the Lyon-based insurer SHAM. Bernard Chauvin is a physician specializing in ophthalmology. He headed the Laboratoires Chauvin for 27 years (until its acquisition by Bausch & Lomb), prior to joining Neurotech, a French biotechnology company where he served as Chief Executive Officer until 2004. Since then, he has taken an active role as a director in the development of a number of pharmaceutical and biotechnology companies.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Bernard Chauvin invests in
Stages Bernard Chauvin invests in
Countries Bernard Chauvin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (100%)
- Health Care 2 (100%)
- Medical Device 1 (50%)
Stage
- Series A 1 (50%)
- Series C 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ciliatech
|
Ciliatech is a medtech company specialized in ophthalmology, develops a new class of implant to address the increasing need to treat glaucoma durably and with very minimal adverse effects. | $1.9M / Series A / Apr 25, 2023 | |
EyeTechCare
|
EyeTechCare has developed a new medical device called EyeOP1. This leading edge technology device is the result of several years of joint research with INSERM which has led to the development of a treatment method using High Intensity Focused Ultrasound (HIFU).EyeOP1 is an ultrasound device which offers a non-invasive treatment for refractoryglaucoma. This new method is extremely accurate, simple and only takes one minute. | $11M / Series C / Mar 12, 2013 |
Co-Investors
About EyeTechCare
EyeTechCare has developed a new medical device called EyeOP1. This leading edge technology device is the result of several years of joint research with INSERM which has led to the development of a treatment method using High Intensity Focused Ultrasound (HIFU).EyeOP1 is an ultrasound device which offers a non-invasive treatment for refractoryglaucoma. This new method is extremely accurate, simple and only takes one minute.
EyeTechCare Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bernard Chauvin
Independent Director
|
|||
Fabrice ROMANO
Founder
|
|||
Laurent Farcy
Co - Founder & Director, Clinical & Regulatory Affairs
|
|||
Philippe Chapuis
Director, Industrial
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bernard Chauvin invest in?
Bernard Chauvin invests primarily in Medical, Health Care and Medical Device startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bernard Chauvin?
Public channels for Bernard Chauvin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bernard Chauvin last invest?
The most recent investment recorded for Bernard Chauvin closed in Apr 2023. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
